---

Clinical effects of half- and full-dose abatacept are equivalent

Full Text PDF

---

Original Article

Author Details : Yasunori Itoh, Wataru Shimada, Masato Kamiya, Masakatsu Saitoh, Osamu Matsuo, Hiraku Kikuchi

Volume : 2, Issue : 1, Year : 2016

Article Page : 33-40

Suggest article by email

Get Permission

Abstract

Objectives: To compare the clinical effect and cost effectiveness of half- and full-dosage abatacept in patients aged over 65 years diagnosed with rheumatoid arthritis.
Methods: Sixty-three elderly patients aged > 65 years with rheumatoid with abatacept were enrolled from four hospitals. Disease Activity Score using C-reactive protein (DAS 28-CRP) were evaluated as well as blood, urine, and radiographic analyses before and 52 weeks after abatacept administration.
Results: DAS 28-CRP decreased from 5.1 ± 0.9 to 2.6 ± 1.0 for half-dosage and from 4.6 ± 1.3 to 2.8 ± 0.9 for full-dosage abatacept, but the differences were not significant. Clinical improvement using DAS 28-CRP was similar in patients aged 65-74 years and those aged > 75 years.
Conclusions: Half-dosage abatacept exhibited the same clinical effect and cost effectiveness of full-dosage of abatacept. And age was not a risk factor for ABT treatment.

Key words: Abatacept, Aged, Clinical equivalence, Half-dose, Rheumatoid arthritis

How to cite : Itoh Y, Shimada W, Kamiya M, Saitoh M, Matsuo O, Kikuchi H, Clinical effects of half- and full-dose abatacept are equivalent. IP Int J Orthop Rheumatol 2016;2(1):33-40

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.